The paclitaxel (H20066640) is produced by Beijing Shuanglu Pharmaceutical Co., Ltd. The carboplatin (H20020181) is produced by Qilu Pharmaceutical Co., Ltd. On the first day, the patient received intravenous infusion of 24 h of paclitaxel injection (135 mg/m2), 20 mg of dexamethasone 12 and 6 h before intravenous infusion of paclitaxel, 25 mg of Promethazine intramuscular injection 30 min before intravenous infusion, and injection carboplatin (area under the receiver operating curve [AUC] = 5) + 5% 500 mL of glucose on the second day.
Paclitaxel
Manufactured by Qilu Pharmaceutical
Sourced in China
Paclitaxel is a chemotherapeutic agent that is used in the manufacture of various pharmaceutical products. It is a natural compound derived from the bark of the Pacific yew tree. Paclitaxel functions as an anti-mitotic agent, inhibiting cell division and promoting the stabilization of microtubules.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using paclitaxel
1
Paclitaxel and Carboplatin Chemotherapy
2
Measuring Chemo-Resistance with CCK-8 Assay
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Cell viability was measured using Cell Counting Kit-8 (CCK-8) cell assay kits (Bestbio, Shanghai, China) according to the manufacturer's protocol. When MCS was established, cells were cultured in fresh media with DDP (in the final concentration of 30 nM or 90 nM) (Qilu Pharmaceutical, Jinan, Shandong, China) or paclitaxel (in the final concentration of 10 nM or 20 nM) (Qilu Pharmaceutical, Jinan, Shandong, China) for 48h. Cell viabilities were calculated based upon the OD values at 450nm. To measure the effect of NSC95397 (Millipore, Darmstadt, Germany) on chemo-resistance, we pre-treated cells with 32 nM NSC95397 for 48h before cultured in media with DDP or paclitaxel.
3
Camrelizumab and Chemotherapy for Cancer Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The eligible patients received the chemotherapy or Camrelizumab plus chemotherapy. The chemotherapy regimens included paclitaxel (Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China), lobaplatin (Hainan Changan International Pharmaceutical Co., Ltd., Hainan, China), oxaliplatin (Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China), cisplatin (Qilu Pharmaceutical Co., Ltd., Shandong, China), ifosfamide (Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China) + carboplatin (Qilu Pharmaceutical Co., Ltd., Shandong, China), gemcitabine (Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China) + paclitaxel, and pemetrexed (Qilu Pharmaceutical Co., Ltd., Shandong, China) + cisplatin. Camrelizumab (Jiangsu Hengrui Pharmaceuticals Co., Ltd., Jiangsu, China) was administered (200-mg) once a day. A cycle of treatment consisted of 21 days
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!